# US 2014/0154781 A1 · Therapeutic Use of Botulinum Neurotoxin in the Treatment of pain associated with diabetic neuropathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154781 A1
- Document ID: US20140154781A1
- Status: Published application
- Kind: A1
- Application number: 14/174,911
- Filed: 2014-02-07
- Published: 2014-06-05
- Earliest claimed: 2008-04-25
- Assignees: Ipsen Pharma S.A.S.
- Applicants: Ipsen Pharma S.A.S.
- Inventors: Christine FAVRE; Michel AUGUET; Piere-Etienne CHABRIER DE LASSAUNIERE
- Web page: https://patentgrep.com/patent/US20140154781A1

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to at least one botulinum neurotoxin for treatment or prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.

## Claims

### Claim 1

At least one botulinum neurotoxin for treatment of pain associated with diabetic neuropathy, wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.

### Claim 2 (depends on 1)

The botulinum neurotoxin according to claim 1, wherein said diabetic neuropathy is diabetic neuropathy of an upper limb.

### Claim 3 (depends on 1)

The botulinum neurotoxin according to claim 1, wherein said diabetic neuropathy is diabetic neuropathy of a lower limb.

### Claim 4

The botulinum neurotoxin according to any one of the preceding claims, prepared for local administration into a limb.

### Claim 5

The botulinum neurotoxin according to any one of the preceding claims, prepared for local administration into a hand or a foot.

### Claim 6

The botulinum neurotoxin according to any one of the preceding claims, prepared for administration into the palm of a hand or the sole of a foot.

### Claim 7

The botulinum neurotoxin according to any one of the preceding claims, prepared for local administration limited to one side of the body.

### Claim 8

The botulinum neurotoxin according to any one of the preceding claims, prepared for administration into a site that is distant from a painful site.

### Claim 9

The botulinum neurotoxin according to any one of the preceding claims, prepared for administration no more frequently than once per month or nor more frequently than once every six weeks or no more frequently than once every 8 weeks.

### Claim 10

The botulinum neurotoxin according to any one of the preceding claims, wherein said local administration is selected from sub-cutaneous, intra-muscular, intradermal or transdermal administration.

### Claim 11

The botulinum neurotoxin according to any one of the preceding claims, wherein the botulinum neurotoxin is selected from botulinum neurotoxin type A, A1, A2, A3, A4, B, C, C1, D, E, F or G.

### Claim 12

The botulinum neurotoxin according to any one of the preceding claims, wherein the botulinum neurotoxin is the botulinum toxin of type A1.

### Claim 13

The botulinum neurotoxin according to any one of the preceding claims, prepared for administration at a dose comprised between 1 U and 1500 U.

### Claim 14

The botulinum neurotoxin according to any one of the preceding claims, prepared for administration at a dose comprised between 100 and 500 U.